Ragweed Pollen Allergy - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Ragweed Pollen Allergy - Pipeline Review, H1 2019’, provides an overview of the Ragweed Pollen Allergy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ragweed Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ragweed Pollen Allergy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ragweed Pollen Allergy

- The report reviews pipeline therapeutics for Ragweed Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Ragweed Pollen Allergy therapeutics and enlists all their major and minor projects

- The report assesses Ragweed Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Ragweed Pollen Allergy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ragweed Pollen Allergy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ragweed Pollen Allergy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

Astellas Pharma Inc

Biomay AG

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

Astellas Pharma Inc

Biomay AG

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ragweed Pollen Allergy - Overview

Ragweed Pollen Allergy - Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ragweed Pollen Allergy - Overview

Ragweed Pollen Allergy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ragweed Pollen Allergy - Therapeutics Assessment

Assessment by Route of Administration

Assessment by Molecule Type

Ragweed Pollen Allergy - Companies Involved in Therapeutics Development

ALK-Abello AS

Allergy Therapeutics Plc

Anergis SA

Astellas Pharma Inc

Biomay AG

Ragweed Pollen Allergy - Drug Profiles

Allergan for Rag Weed Pollen Allergy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BM-34 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LAMP-Vax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pollinex Ragweed - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ragweed Pollen Allergy - Dormant Projects

Ragweed Pollen Allergy - Discontinued Products

Ragweed Pollen Allergy - Product Development Milestones

Featured News & Press Releases

Feb 16, 2017: ALK submits registration application for ragweed SLIT-tablet in Europe

Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR

May 15, 2014: Ragwitek, An Allergy Immunotherapy Tablet For The Treatment Of Signs And Symptoms Of Ragweed Allergy, Is Now Available In Canada

Apr 17, 2014: FDA Approves Merck’s RAGWITEK Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults

Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet

May 08, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet

Mar 11, 2013: ALK’s Partner Merck Submits BLA To FDA For Marketing Authorization For Ragweed AIT

Feb 22, 2013: Merck To Present New Data Analyses Of Its Investigational Ragweed Pollen And Grass Pollen Allergy Immunotherapy Tablets At 2013 AAAAI Annual Meeting

Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting

Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Ragweed Pollen Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under ...

List of Tables

Number of Products under Development for Ragweed Pollen Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Ragweed Pollen Allergy - Pipeline by ALK-Abello AS, H1 2019

Ragweed Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2019

Ragweed Pollen Allergy - Pipeline by Anergis SA, H1 2019

Ragweed Pollen Allergy - Pipeline by Astellas Pharma Inc, H1 2019

Ragweed Pollen Allergy - Pipeline by Biomay AG, H1 2019

Ragweed Pollen Allergy - Dormant Projects, H1 2019

Ragweed Pollen Allergy - Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for Ragweed Pollen Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of ...

List of Figures

Number of Products under Development for Ragweed Pollen Allergy, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports